Clinical Trials Logo

Colchicine clinical trials

View clinical trials related to Colchicine.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06215989 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Treatment of ACuTe Coronary Syndromes With Low-dose colchICine

Start date: May 2024
Phase: N/A
Study type: Interventional

This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.

NCT ID: NCT05361772 Not yet recruiting - Clinical trials for Abdominal Aortic Aneurysm

Low-dose Colchicine Inhibit Abdominal Aortic Aneurysm Growth Trial

COIN
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

COIN trial is a a prospective, randomized, placebo-controlled, double-blind, multicenter clinical study. Approximately 230 patients with small abdominal aortic aneurysms (AAA) will be randomly allocated to low-dose colchicine group or placebo group. All study patients will be followed up in the outpatient clinic every 3 months and undergo CTA scans after 24 months from randomization. The primary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA diameter. The secondary objective is to test the hypothesis that low dose colchicine can inhibit the progression of AAA volume, reduce the incidence of clinical outcomes associated with AAA, reduce the incidence of major adverse cardiovascular events and all-cause mortality.

NCT ID: NCT05038449 Not yet recruiting - Covid19 Clinical Trials

Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19

Start date: September 6, 2021
Phase: N/A
Study type: Interventional

This study is designed for single-center, randomized, open label, standard therapy controlled. 60 COVID-19 subjects with a treatment period of 10 days and follow-up until 28 days after enrollment.